DiMe also collaborates with major pharmaceuticals, suppliers of the latest digital end -to -end packaging

The Digital Medicine Society (DiMe) has teamed up with a number of major pharmaceutical companies and providers to launch a digital solution. tools for related issues.

The open-access app, obtained from a partnership between DiMe, Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op, gives payers a roadmap for integration. Providing digital endpoints on reimbursement for new medications. Called the 3Ps toolkit, it provides detailed insights for medications and fees, as well as information for patients and patient organizations.

“A more common result is a specificity that has already been described and can be seen as a result of a medical test in order to say that the trial is accurate,” he said. Jennifer Goldsack, CEO of DiMe, said MobiHealthNews.

Goldsack gave the example of people with heart disease, where the hospital was closed or the time of death. There are many types of results, he said, including blood tests, personal information and photographs.

“Then, obviously in the digital age, we have these measurements made by a sensor that can measure things that we couldn’t measure before. They can measure the effects of the sensor. interest with large .. low load, with very high resolution.

“There’s no doubt that digital statistics provide unique opportunities for the development of therapies that are relevant to patients,” Goldsack said.

The digital endpoints contain the information produced by the sensor, which can be obtained from a variety of sources such as smart watches, telephones, mattresses, contact scales and contact lenses.

Included in this new toolbox is a glossary of words, a quick start guide to drug reimbursement in the U.S. and Europe, and information on the times and challenges in implementation. Technology.

“It’s kind of a high -powered, multidisciplinary team of highly thought -provoking professionals at the top of this field that we say we believe in using digital statistics. The problem is going to be slow or slow. inefficiencies in taking new drugs that are developed using the latest numbers on the market, ”Goldsack said.

Why it is

The use of digital numbers in research is growing rapidly. In fact, in the past month the The FDA has issued guidelines for the use of medical data in clinical trials. This innovation is intended to speed up the conversation about inclusion.

“We have thought a lot, as a profession, about the use of these kinds of digital measurement products, these digital information, the digital effects for drug development. to do, ”Goldsack said. “Today, we thought a little bit about the approval of the payroll and technology-review company.”


This isn’t the first time DiMe has been involved in digital-end gaming. In November, the company announced partnering with pharmaceutical giants AbbVie, Janssen Research and Development, Novartis, Pfizer and UCB to create night scrub a solution for atopic dermatitis.


“In initiating these new tips and resources, we will be the first to identify and discuss the need to ensure that data from digital results can be developed in a manner that is acceptable to the public. payers and regulators, ”Goldsack said in a statement.

“We appreciate the first hand experience of our colleagues in this project and we are proud to provide these resources before delaying the provision of appropriate medications to patients who need it. it must be. “

Related Posts

Leave a Reply

Your email address will not be published.